Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:OPTNASDAQ:SOPHNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$57.77+2.7%$64.30$47.86▼$107.37$3.18B0.34577,087 shs1.24 million shsOPTOpthea$3.41$3.40$1.79▼$6.30$524.84M1.1226,659 shsN/ASOPHSOPHiA GENETICS$2.93-2.0%$3.05$2.58▼$6.28$195.33M1.0362,572 shs15,281 shsVKTXViking Therapeutics$27.61-0.9%$26.19$18.92▼$81.73$3.10B0.754.11 million shs1.73 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+2.31%-11.87%-2.35%-13.66%+10.56%OPTOpthea0.00%0.00%0.00%-40.02%+4.28%SOPHSOPHiA GENETICS-2.01%-3.30%-0.34%-19.73%-36.30%VKTXViking Therapeutics-0.86%-5.96%+19.52%-15.20%-65.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.6558 of 5 stars3.60.00.00.02.62.50.0OPTOpthea0.8149 of 5 stars2.11.00.00.02.70.80.6SOPHSOPHiA GENETICS2.0768 of 5 stars3.45.00.00.01.10.00.6VKTXViking Therapeutics4.5849 of 5 stars4.52.00.04.73.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$109.3189.21% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80132.08% UpsideVKTXViking Therapeutics 3.00Buy$87.15215.66% UpsideCurrent Analyst Ratings BreakdownLatest OPT, VKTX, ACLX, and SOPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.00(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M29.48N/AN/A$9.97 per share5.79OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09SOPHSOPHiA GENETICS$67.17M2.91N/AN/AN/A∞VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%N/AOPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/ASOPHSOPHiA GENETICS-$78.98M-$1.00N/AN/AN/A-110.71%-55.06%-38.33%N/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest OPT, VKTX, ACLX, and SOPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 million2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29OPTOptheaN/A2.942.94SOPHSOPHiA GENETICS0.123.803.59VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%OPTOpthea55.95%SOPHSOPHiA GENETICS31.59%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACLXArcellx6.24%OPTOpthea3.20%SOPHSOPHiA GENETICS4.88%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.07 million50.70 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableOPT, VKTX, ACLX, and SOPH HeadlinesRecent News About These CompaniesDAFNA Capital Management LLC Lowers Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 10 at 7:30 AM | marketbeat.comBoone Capital Management LLC Boosts Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 8 at 6:30 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Position Lifted by Braidwell LPMay 8 at 6:29 AM | marketbeat.comAptus Capital Advisors LLC Purchases 10,564 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 8 at 4:57 AM | marketbeat.comCantor Fitzgerald L. P. Takes $380,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 7 at 6:53 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Bamco Inc. NYMay 7 at 5:58 AM | marketbeat.comAQR Capital Management LLC Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 6, 2025 | marketbeat.comWhy Viking Therapeutics Stock Surged Nearly 20% Higher in AprilMay 6, 2025 | fool.comApis Capital Advisors LLC Has $3.86 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 5, 2025 | marketbeat.com5AM Venture Management LLC Has $7.63 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 4, 2025 | marketbeat.com683 Capital Management LLC Lowers Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 4, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by MML Investors Services LLCMay 4, 2025 | marketbeat.comResearch Analysts Set Expectations for VKTX FY2025 EarningsMay 3, 2025 | marketbeat.comViking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025May 3, 2025 | finance.yahoo.comWhy Viking Therapeutics Stock Was Victorious This WeekMay 2, 2025 | fool.comWhy Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped FridayMay 2, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Raised to "Strong-Buy" at Cantor FitzgeraldMay 2, 2025 | marketbeat.comWhere Will Viking Therapeutics Be in 3 Years?May 2, 2025 | fool.comTraders Purchase Large Volume of Viking Therapeutics Call Options (NASDAQ:VKTX)May 2, 2025 | marketbeat.comBrokers Offer Predictions for VKTX FY2025 EarningsMay 2, 2025 | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Up - What's Next?May 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryCrowdStrike Stock Is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock Is a Buy as Cyberthreat Environment ExpandsUnusual Options Activity Signals Bullish Shift to Travel StocksBy Gabriel Osorio-Mazilli | April 22, 2025View Unusual Options Activity Signals Bullish Shift to Travel StocksOPT, VKTX, ACLX, and SOPH Company DescriptionsArcellx NASDAQ:ACLX$57.77 +1.51 (+2.68%) As of 05/9/2025 03:52 PM EasternArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 05/9/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.SOPHiA GENETICS NASDAQ:SOPH$2.93 -0.06 (-2.01%) As of 05/9/2025 03:59 PM EasternSOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Viking Therapeutics NASDAQ:VKTX$27.61 -0.24 (-0.86%) As of 05/9/2025 03:58 PM EasternViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
